Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
OLIVEIRA, Victoria Camargos de
IRBER, Flavia Mariana
ANGERVILLE, Bernard
CAMPOS, Marcela Waisman
TORALES, Julio
VENTRIGLIO, Antonio
Citação
INTERNATIONAL REVIEW OF PSYCHIATRY, v.35, n.5-6, Special Issue, p.397-417, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavioural support. Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated. Smoking cessation medications have been shown to be effective in reducing nicotine cravings and withdrawal symptoms and promoting smoking cessation among patients living with mental disorders. However, these medications may have implications for patients' mental health and need to be monitored closely. The efficacy and side effects of these medications may vary depending on the patient's psychiatric condition, medication regimen, substance use, or medical comorbidities. The purpose of this review is to synthesise the pharmacokinetics, pharmacodynamics, therapeutic effects, adverse effects, and pharmacological interactions of first- and second-line smoking cessation drugs, with an emphasis on patients suffering from mental illnesses. Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients' needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.
Palavras-chave
Smoking, mental health, psychopharmacology, interactions, cessation
URI
https://observatorio.fm.usp.br/handle/OPI/59113
Referências
  1. Altarawneh S, 2013, J PROSTHODONT, V22, P13, DOI 10.1111/j.1532-849X.2012.00906.x
  2. [Anonymous], 2019, WHO REPORT GLOBAL TO
  3. Anthenelli RM, 2019, J GEN INTERN MED, V34, P862, DOI 10.1007/s11606-019-04858-2
  4. Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0
  5. Aubin HJ, 2016, J CLIN PSYCHIAT, V77, pE906, DOI 10.4088/JCP.16lr10669
  6. Aubin HJ, 2012, NEUROSCI BIOBEHAV R, V36, P271, DOI 10.1016/j.neubiorev.2011.06.007
  7. Aubin HJ, 2011, CURR PHARM DESIGN, V17, P1343, DOI 10.2174/138161211796150837
  8. Aveyard P, 2008, BMJ-BRIT MED J, V336, P1223, DOI 10.1136/bmj.39545.852616.BE
  9. Ayers CR, 2020, DEPRESS ANXIETY, V37, P247, DOI 10.1002/da.22982
  10. Balmford J, 2011, NICOTINE TOB RES, V13, P94, DOI 10.1093/ntr/ntq215
  11. Barboza JL, 2016, EXPERT OPIN PHARMACO, V17, P1483, DOI 10.1080/14656566.2016.1197203
  12. Beard E, 2021, ADDICTION, V116, P2816, DOI 10.1111/add.15440
  13. Benowitz NL, 2009, ANNU REV PHARMACOL, V49, P57, DOI 10.1146/annurev.pharmtox.48.113006.094742
  14. Berm E, 2016, PHARMACOPSYCHIATRY, V49, P186, DOI 10.1055/s-0042-105443
  15. Bertilsson L, 2007, CLIN PHARMACOL THER, V82, P606, DOI 10.1038/sj.clpt.6100358
  16. Bis-Humbert C, 2021, EUR J PHARMACOL, V910, DOI 10.1016/j.ejphar.2021.174465
  17. BoehringerIngelheim, 1998, CAT CLON HYDR USP PR
  18. BREDFELDT RC, 1989, J FAM PRACTICE, V29, P153
  19. Bruijnzeel AW, 2010, PSYCHOPHARMACOLOGY, V212, P485, DOI 10.1007/s00213-010-1970-0
  20. Burstein AH, 2006, J CLIN PHARMACOL, V46, P1234, DOI 10.1177/0091270006291837
  21. Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]
  22. Cahill Kate, 2016, Cochrane Database Syst Rev, pCD006103, DOI 10.1002/14651858.CD006103.pub7
  23. Castaldelli-Maia JM, 2018, EUR PSYCHIAT, V52, P22, DOI 10.1016/j.eurpsy.2018.02.005
  24. Castaldelli-Maia JM, 2014, INT REV PSYCHIATR, V26, P515, DOI 10.3109/09540261.2014.928272
  25. Castaldelli-Maia JM, 2013, REV BRAS PSIQUIATR, V35, P338, DOI 10.1590/1516-4446-2012-0907
  26. Chao CT, 2012, J FORMOS MED ASSOC, V111, P51, DOI 10.1016/j.jfma.2011.01.001
  27. Chengappa KNR, 2014, J CLIN PSYCHIAT, V75, P765, DOI 10.4088/JCP.13m08756
  28. Coe JW, 2005, J MED CHEM, V48, P3474, DOI 10.1021/jm050069n
  29. Correa JB, 2021, NICOTINE TOB RES, V23, P1646, DOI 10.1093/ntr/ntab056
  30. Costa R, 2019, DRUG METAB REV, V51, P293, DOI 10.1080/03602532.2019.1620763
  31. Coustals N, 2020, SCHIZOPHR RES, V222, P113, DOI 10.1016/j.schres.2020.03.071
  32. Crawford P., 2017, AM FAM PHYSICIAN, V96
  33. Cullum JL, 2004, CAN J PSYCHIAT, V49, P139, DOI 10.1177/070674370404900209
  34. da Costa CL, 2002, CHEST, V122, P403, DOI 10.1378/chest.122.2.403
  35. Dean L., 2012, Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype
  36. Delanty N, 1998, LANCET, V352, P383, DOI 10.1016/S0140-6736(98)02158-8
  37. Dempsey D, 2004, CLIN PHARMACOL THER, V76, P64, DOI 10.1016/j.clpt.2004.02.011
  38. Desai HD, 2001, CNS DRUGS, V15, P469, DOI 10.2165/00023210-200115060-00005
  39. Devi RE, 2020, J FAM MED PRIM CARE, V9, P2615, DOI 10.4103/jfmpc.jfmpc_313_20
  40. Dunner DL, 1998, J CLIN PSYCHIAT, V59, P366, DOI 10.4088/JCP.v59n0705
  41. Ebbert J, 2021, MAYO CLIN PROC, V96, P1801, DOI 10.1016/j.mayocp.2020.10.046
  42. EDINGTON RF, 1980, CAN MED ASSOC J, V123, P23
  43. Elrashidi MY, 2014, EXPERT OPIN EMERG DR, V19, P243, DOI 10.1517/14728214.2014.899580
  44. European Medicines Agency, CHAMP SUMM PROD CHAR
  45. Evins AE, 2021, PSYCHIAT SERV, V72, P7, DOI 10.1176/appi.ps.202000032
  46. Evins AE, 2019, J CLIN PSYCHOPHARM, V39, P108, DOI 10.1097/JCP.0000000000001015
  47. Evins AE, 2015, HARVARD REV PSYCHIAT, V23, P90, DOI 10.1097/HRP.0000000000000063
  48. Faber MS, 2004, CLIN PHARMACOL THER, V76, P178, DOI 10.1016/j.clpt.2004.04.003
  49. Faessel HM, 2006, J CLIN PHARMACOL, V46, P1439, DOI 10.1177/0091270006292624
  50. Faessel HM, 2010, CLIN PHARMACOKINET, V49, P799, DOI 10.2165/11537850-000000000-00000
  51. Faucette SR, 2000, DRUG METAB DISPOS, V28, P1222
  52. Fava Maurizio, 2005, Prim Care Companion J Clin Psychiatry, V7, P106
  53. FDA, 2016, VAR MARK INF
  54. Ferguson SG, 2011, ADDICT BEHAV, V36, P713, DOI 10.1016/j.addbeh.2011.02.002
  55. FINDLAY JWA, 1981, EUR J CLIN PHARMACOL, V21, P127, DOI 10.1007/BF00637513
  56. Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244
  57. Foley KF, 2006, EXPERT REV NEUROTHER, V6, P1249, DOI 10.1586/14737175.6.9.1249
  58. FRANKS P, 1989, JAMA-J AM MED ASSOC, V262, P3011, DOI 10.1001/jama.262.21.3011
  59. Frishman William H, 2006, Cardiol Rev, V14, P57, DOI 10.1097/01.crd.0000172309.06270.25
  60. Gardner JS, 2000, PHARMACOTHERAPY, V20, P1423, DOI 10.1592/phco.20.19.1423.34854
  61. Garrison GD, 2009, CLIN THER, V31, P463, DOI 10.1016/j.clinthera.2009.03.021
  62. GINSBURG J, 1985, BRIT J OBSTET GYNAEC, V92, P1169, DOI 10.1111/j.1471-0528.1985.tb03032.x
  63. Giulietti F, 2020, HIGH BLOOD PRESS CAR, V27, P349, DOI 10.1007/s40292-020-00396-9
  64. GLASSMAN AH, 1988, JAMA-J AM MED ASSOC, V259, P2863
  65. Glaxo-SmithKline, 1998, STUD AK1A1003
  66. GlaxoSmithKline, 2009, FDA PRESCR INF BUPR
  67. GOETZ CG, 1984, NEUROLOGY, V34, P1092, DOI 10.1212/WNL.34.8.1092
  68. GOLD MS, 1993, PSYCHIAT CLIN N AM, V16, P61
  69. Gómez-Coronado N, 2018, PHARMACOTHERAPY, V38, P235, DOI 10.1002/phar.2073
  70. GOURLAY S, 1994, CLIN PHARMACOL THER, V55, P64, DOI 10.1038/clpt.1994.11
  71. Gourlay S G, 2004, Cochrane Database Syst Rev, pCD000058, DOI 10.1002/14651858.CD000058.pub2
  72. Gowing L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002024.pub4
  73. Gupta R., 2019, INT J ORAL HLTH DENT, V5, P69, DOI [https://doi.org/10.18231/j.ijohd.2019.017, DOI 10.18231/J.IJOHD.2019.017]
  74. HAO W, 1988, BRIT J ADDICT, V83, P1221
  75. Hartwell KJ, 2013, AM J DRUG ALCOHOL AB, V39, P92, DOI 10.3109/00952990.2012.750665
  76. Hashemi SN, 2012, CLIN PHARMACOL-ADV A, V4, P1, DOI 10.2147/CPAA.S23831
  77. Haslemo T, 2006, EUR J CLIN PHARMACOL, V62, P1049, DOI 10.1007/s00228-006-0209-9
  78. Haustein KO, 2003, NICOTINE TOB RES, V5, P195, DOI 10.1080/146222003100073676
  79. Heffner JL, 2019, J AFFECT DISORDERS, V256, P267, DOI 10.1016/j.jad.2019.06.008
  80. Hefner G, 2014, J CLIN PSYCHOPHARM, V34, P394, DOI 10.1097/JCP.0000000000000127
  81. Hicks JK, 2013, CLIN PHARMACOL THER, V93, P402, DOI 10.1038/clpt.2013.2
  82. Hiemke C, 2011, PHARMACOPSYCHIATRY, V44, P195, DOI 10.1055/s-0031-1286287
  83. Hitsman B, 2009, CAN J PSYCHIAT, V54, P368, DOI 10.1177/070674370905400604
  84. Howes S, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000031.pub5
  85. Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub4, 10.1002/14651858.CD000031.pub3]
  86. Hughes JR, 2005, NICOTINE TOB RES, V7, P491, DOI 10.1080/14622200500185298
  87. Hukkanen J, 2005, PHARMACOL REV, V57, P79, DOI 10.1124/pr.57.1.3
  88. Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703
  89. Jefferson James W, 2008, Expert Rev Neurother, V8, P715, DOI 10.1586/14737175.8.5.715
  90. Jefferson JW, 2005, CLIN THER, V27, P1685, DOI 10.1016/j.clinthera.2005.11.011
  91. Jordan CJ, 2018, EXPERT OPIN DRUG DIS, V13, P671, DOI 10.1080/17460441.2018.1458090
  92. Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56
  93. Jorgensen CK, 2021, SYST REV-LONDON, V10, DOI 10.1186/s13643-021-01789-0
  94. Kennedy SH, 2002, J CLIN PSYCHIAT, V63, P181, DOI 10.4088/JCP.v63n0302
  95. KETTER TA, 1995, J CLIN PSYCHOPHARM, V15, P327, DOI 10.1097/00004714-199510000-00004
  96. Khan S R, 2016, Profiles Drug Subst Excip Relat Methodol, V41, P1, DOI 10.1016/bs.podrm.2015.12.001
  97. King DP, 2012, NEUROPSYCHOPHARMACOL, V37, P641, DOI 10.1038/npp.2011.232
  98. Kirchheiner J, 2001, ACTA PSYCHIAT SCAND, V104, P173, DOI 10.1034/j.1600-0447.2001.00299.x
  99. Knadler MP, 2011, CLIN PHARMACOKINET, V50, P281, DOI 10.2165/11539240-000000000-00000
  100. Köhler-Forsberg O, 2019, BRIT J PSYCHIAT, V215, P494, DOI 10.1192/bjp.2018.302
  101. Kortmann GL, 2010, AM J MED GENET B, V153B, P17, DOI 10.1002/ajmg.b.30978
  102. Kotz D, 2021, NPJ PRIM CARE RESP M, V31, DOI 10.1038/s41533-021-00259-3
  103. Laine K, 2001, CLIN PHARMACOL THER, V70, P327, DOI 10.1067/mcp.2001.118523
  104. LECKMAN JF, 1985, NEUROLOGY, V35, P343, DOI 10.1212/WNL.35.3.343
  105. Lee EJ, 2020, PSYCHIAT QUART, V91, P263, DOI 10.1007/s11126-019-09689-2
  106. Lesage E, 2017, JAMA PSYCHIAT, V74, P632, DOI 10.1001/jamapsychiatry.2017.0400
  107. Lewis A, 2007, NEUROTOXICOLOGY, V28, P182, DOI 10.1016/j.neuro.2006.05.019
  108. Lima DR, 2020, J PSYCHIATR RES, V125, P121, DOI 10.1016/j.jpsychires.2020.03.014
  109. Lind AB, 2009, CLIN PHARMACOKINET, V48, P63, DOI 10.2165/0003088-200948010-00005
  110. Loreto AR, 2017, J DUAL DIAGN, V13, P238, DOI 10.1080/15504263.2017.1328149
  111. Loughead J, 2010, BIOL PSYCHIAT, V67, P715, DOI 10.1016/j.biopsych.2010.01.016
  112. LOWENTHAL DT, 1988, CLIN PHARMACOKINET, V14, P287, DOI 10.2165/00003088-198814050-00002
  113. Lundstrom NH, 2022, ACTA NEUROPSYCHIATR, V34, P1, DOI 10.1017/neu.2021.28
  114. Manakil J., 2020, EUR J GEN DENT, V9, P1, DOI [https://doi.org/10.4103/ejgd.ejgd_100_19, DOI 10.4103/EJGD.EJGD_100_19]
  115. Maneeton N, 2013, DRUG DES DEV THER, V7, P1053, DOI 10.2147/DDDT.S46849
  116. MANHEM P, 1985, ALCOHOL CLIN EXP RES, V9, P238, DOI 10.1111/j.1530-0277.1985.tb05743.x
  117. Mansbach RS, 2000, PSYCHOPHARMACOLOGY, V148, P234, DOI 10.1007/s002130050047
  118. Mansvelder HD, 2002, J NEUROBIOL, V53, P606, DOI 10.1002/neu.10148
  119. McDonough M, 2015, AUST PRESCR, V38, P106, DOI 10.18773/austprescr.2015.038
  120. MELLSTROM B, 1981, DRUG METAB DISPOS, V9, P565
  121. Mendelsohn CP, 2015, AUSTRALAS PSYCHIATRY, V23, P37, DOI 10.1177/1039856214562076
  122. Merwar G., 2021, NORTRIPTYLINE
  123. Mills E. J., 2018, TOBINDUC DIS, V16, P14
  124. Minichino A, 2013, INT J ENV RES PUB HE, V10, P4790, DOI 10.3390/ijerph10104790
  125. Molander L, 2001, CLIN PHARMACOL THER, V69, P57, DOI 10.1067/mcp.2001.113181
  126. Molyneaux E, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004363.pub3
  127. Molyneux A, 2004, Cas Lek Cesk, V143, P781
  128. Moss EL, 2006, PSYCHO-ONCOLOGY, V15, P259, DOI 10.1002/pon.952
  129. Murray CJL, 2020, LANCET, V396, P1223, DOI [10.1016/S0140-6736(20)30752-2, 10.1016/S0140-6736(20)30925-9]
  130. Nides M, 2008, AM J MED, V121, pS20, DOI 10.1016/j.amjmed.2008.01.016
  131. Nims RW, 1997, DRUG METAB DISPOS, V25, P750
  132. NORDIN C, 1995, CLIN PHARMACOKINET, V28, P26, DOI 10.2165/00003088-199528010-00004
  133. Obach RS, 2006, DRUG METAB DISPOS, V34, P121, DOI 10.1124/dmd.105.006767
  134. Olesen OV, 1997, DRUG METAB DISPOS, V25, P740
  135. Oon-arom A, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107631
  136. ORNISH SA, 1988, ARCH INTERN MED, V148, P2027, DOI 10.1001/archinte.148.9.2027
  137. Pachas GN, 2012, J DUAL DIAGN, V8, P117, DOI 10.1080/15504263.2012.663675
  138. Perez-Paramo YX, 2021, EXPERT OPIN DRUG MET, V17, P333, DOI 10.1080/17425255.2021.1863948
  139. Pfizer Labs, CHANT VAR TABL PROD
  140. Piatkov Irina, 2011, ISRN Pharm, V2011, P805983, DOI 10.5402/2011/805983
  141. Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413
  142. Preskorn S., 2004, OTHER ANTIDEPRESSANT, V157, P263
  143. Prevention T., 2016, ENSP GUID TREAT TOB
  144. PROCHAZKA AV, 1992, ARCH INTERN MED, V152, P2065, DOI 10.1001/archinte.152.10.2065
  145. Ragg M, 2013, AUSTRALAS PSYCHIATRY, V21, P238, DOI 10.1177/1039856213486213
  146. Reynolds CF, 1999, AM J PSYCHIAT, V156, P1177
  147. Roberts LW, 2017, ACAD PSYCHIATR, V41, P441, DOI 10.1007/s40596-017-0738-9
  148. Ross Sarah, 2005, Expert Opin Drug Saf, V4, P995, DOI 10.1517/14740338.4.6.995
  149. Rudorfer MV, 1999, CELL MOL NEUROBIOL, V19, P373, DOI 10.1023/A:1006949816036
  150. Ryu S, 2017, CTS-CLIN TRANSL SCI, V10, P93, DOI 10.1111/cts.12451
  151. Safarinejad MR, 2011, J PSYCHOPHARMACOL, V25, P370, DOI 10.1177/0269881109351966
  152. Safarinejad MR, 2010, BJU INT, V106, P840, DOI 10.1111/j.1464-410X.2009.09154.x
  153. Sager JE, 2016, ACS MED CHEM LETT, V7, P791, DOI 10.1021/acsmedchemlett.6b00189
  154. Schwasinger-Schmidt T E, 2019, Handb Exp Pharmacol, V250, P325, DOI 10.1007/164_2018_167
  155. Shepherd G, 2005, PHARMACOTHERAPY, V25, P1378, DOI 10.1592/phco.2005.25.10.1378
  156. Siu ECK, 2007, ANNU REV PHARMACOL, V47, P541, DOI 10.1146/annurev.pharmtox.47.120505.105354
  157. Sneader W, 2005, DRUG DISCOVERY: A HISTORY, P188
  158. Solai LK, 2002, J CLIN PSYCHOPHARM, V22, P481, DOI 10.1097/00004714-200210000-00007
  159. Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3
  160. Stead LF, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub3
  161. Steimer W, 2005, CLIN CHEM, V51, P376, DOI 10.1373/clinchem.2004.041327
  162. Sumana C. K., 2018, J MED RADIOL PATHOL, V5, P6, DOI https://doi.org/10.15713/ins.jmrps.117
  163. Sweeney CT, 2001, CNS DRUGS, V15, P453, DOI 10.2165/00023210-200115060-00004
  164. Tam J, 2020, PREV MED, V140, DOI 10.1016/j.ypmed.2020.106241
  165. Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420
  166. Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9
  167. Taylor G, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1151
  168. Taylor GMJ, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013522.pub2
  169. The Royal Australian New Zealand College of Psychiatrists, 2022, MENT HLTH CLIN GUID
  170. Thieme D, 2008, INT J LEGAL MED, V122, P149, DOI 10.1007/s00414-007-0184-4
  171. Thomas Kyla H, 2021, Health Technol Assess, V25, P1, DOI 10.3310/hta25590
  172. Toce MS, 2018, J MED TOXICOL, V14, P306, DOI 10.1007/s13181-018-0685-1
  173. Tonstad S, 2020, CURR MED RES OPIN, V36, P713, DOI 10.1080/03007995.2020.1729708
  174. Tsuda Y, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004216
  175. Uher R, 2009, BRIT J PSYCHIAT, V194, P252, DOI 10.1192/bjp.bp.108.057554
  176. United States Department of Health and Human Services, 2020, Smoking cessation. a report of the Surgeon General
  177. Verpeut JL, 2014, EXPERT OPIN DRUG SAF, V13, P831, DOI 10.1517/14740338.2014.909405
  178. Wadgave U, 2016, INT J HEALTH SCI-IJH, V10, P425
  179. Wagena EJ, 2005, ADDICTION, V100, P317, DOI 10.1111/j.1360-0443.2005.00998.x
  180. Wang YY, 2019, PSYCHIAT RES, V272, P155, DOI 10.1016/j.psychres.2018.12.064
  181. Waxmonsky James G, 2005, Essent Psychopharmacol, V6, P262
  182. West R, 2018, ADDICTION, V113, P1507, DOI 10.1111/add.14208
  183. Williams JM, 2012, J CLIN PSYCHIAT, V73, P654, DOI 10.4088/JCP.11m07522
  184. Wu P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-300
  185. Xi ZX, 2010, DRUG HEALTHC PATIENT, V2, P39
  186. Xiao D, 2020, J ADDICT MED, V14, P69, DOI 10.1097/ADM.0000000000000547
  187. Yan T, 2021, CAN FAM PHYSICIAN, V67, P743, DOI 10.46747/cfp.6710743
  188. Yasaei R., 2021, CLONIDINE
  189. Yildiz D, 2004, TOXICON, V43, P619, DOI 10.1016/j.toxicon.2004.01.017
  190. Zevin S, 1999, CLIN PHARMACOKINET, V36, P425, DOI 10.2165/00003088-199936060-00004
  191. Ziedonis D, 2008, NICOTINE TOB RES, V10, P1691, DOI 10.1080/14622200802443569
  192. Zierler-Brown SL, 2007, ANN PHARMACOTHER, V41, P95, DOI 10.1345/aph.1H310

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPer